We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
European Commission approved Zepzelca and atezolizumab combination for aggressive lung cancer. 27% reduction in risk of death. Learn details about the new standard of therapy.
